⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYTX News
Kyverna Therapeutics, Inc. Common Stock
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
globenewswire.com
KYTX
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
KYTX
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
globenewswire.com
KYTX
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
globenewswire.com
KYTX
Form 8-K
sec.gov
KYTX
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
globenewswire.com
KYTX